Welcome to the Newcomer podcast. I'm Eric newcomer, thrilled to
have Naima Raza, independent journalist, Co host of Smart
Girl Dumb Questions here with me.
We are about to together host Deus Ex Medicina, our brand new
AI health and longevity summit. Naima, welcome to the show.
Well, hi Eric, thank you for having me.
I feel like these are like our wedding vows or something.
You're the pro, so really you should be guiding us through
this podcast. Oh, I don't know.
I somehow it was like a long con.
I somehow got Eric to. I'm like, I would love if we can
collaborate on a conference. We tell people a story of why
we're doing this thing. So what is the story?
I remember we got coffee and I was like, wow, now you must
seems to really like know everybody excited, cool,
something I want to do stuff with and like we were kicking
around conference ideas. I don't know what.
What's the story in your mind or how did this all come together?
Yeah. So what happened was I remember
Eric, you had tweeted something or you actually wrote a, you
wrote a sub stack. It was like October of 2024.
And I get the sub stack from Eric.
And it's basically like, oh, you know, ever since I left the
media business, this dying media business, which I was covering
at the time because I was doing a show with Ben Smith at
Semaphore called Mixed Signals, which she still does with
Maktani. It's awesome.
You should check it out. But you know, you're like, I'm
leaving this dying. I've left this dying media,
legacy media business and I just made $4 million and I'm hiring
people. I don't think it was 4 million.
Yeah, yeah. How many millions went there?
Revenue on a million, 2,000,000 plus revenue on a million and
profit is basically what we said with ambitions to sort of
continue to grow it. Yeah, I really put out the bad
signal that we were a media business with money and wanted
more respect and, you know, wanted to work with fun, cool
people. Yeah, in Jay-Z language, that's
known as this for those watching on YouTube.
It's just that it's. Just everybody else brags about
how much money they raised, and here we're a business making
money. At some point, you just need to
say, well, here's here's what's going on.
Which is awesome. So congratulations, Eric.
And I was like, you know, we'd met each other before we'd met
at the code conference. We kind of had people in common
and I wrote, I reached out to you and I was like, hey, Eric,
you have this great business. You're looking to do more
events. I don't want a job, but I want
to go and host things because I love, I love, I love
interviewing people. That's my bread butter.
I love doing stage events. I'm a big believer in the return
to live in the age of AI and, and if you want to, if you have
the infrastructure to handle all this, like I would love to
partner with you editorially. That's what happened.
I think we're both spiritually similar and we love to host.
We're very, we're different people, obviously.
But I was saying to someone literally yesterday I was like,
you know, we hosted the first Ruble Valley AI Summit the same
year I got married. And it's like, oh, I love being
a groom. I love everybody so excited.
So I meet you. It's like it's hard to network.
Any other way we provide. The taste.
Yes, yeah, that's true. I I, yeah, I love, see, I love
to host, but I think the actual infrastructure around it,
there's so much that goes into an event.
There's an amazing team, people like Riley, so many people have
been involved in helping boost and support this event.
And that's the stuff that even though I came up as a producer,
I'm like, I love, I love the stage stuff.
I love having the conversation, thinking about what we're going
to talk about. And I couldn't be more excited
because you have killed it in this AI event space.
And I, I just think we're ripe to have a conversation about
this next era in American healthcare in a way that really
bridges the technology, the AI, the consumer trends, the policy
shift. And I'm so excited to be doing
this on September 9th in San Francisco.
So Dave sex medicina we we agonized over the name.
I don't know if you've noticed whether Twitter is like auto
correcting it out of Latin because it's like it's
translating it for you. So AI is ruining our beautiful
name. I can only imagine Grok AI does
not like anybody else being called.
Or where? Or you're just off.
No I'm not. I just, I'm like, no, I like to
thirst trap with my pictures on Instagram like a real
millennial. I see just.
And you're super. Now you know.
Exactly. No, but I can, I can imagine
that that croc and X might not like anyone else being called
DX, you know, being called God and.
I see it's the X. They're they're sabotaging us.
But yeah, I mean, we really saw, you know, we've been hosting
Cerebral Valley since March 2023.
Obviously that's really focused on sort of foundation models and
people, you know, building software.
You know, we had anthropic CEO Alexander Wang at scale just in
London. We had, you know, Dart, Uber,
what we didn't have a lot of the health piece of it, but that was
clearly becoming a larger and larger piece of the AI story.
So there was that. There was sort of this longevity
thing that's been going on. And then there's sort of all the
change that's happening, whatever you think about it,
because of what's happening with Maha, RFK and the Trump
administration. So I just like, you know,
together we were like, oh, you know, there are these like 3
wild themes and it's a little, it's a little wild.
But I do think going into it, we are like, oh, there's a set of
Silicon Valley people that are going to get it.
Like this is just like the first cerebral Valley where if you're
paying attention, you're like, oh man, there are a lot of
interesting things going on at once that Silicon Valley loves
because that means things are investable.
I mean. You're, you're a technology
journalist as, as your build, but I have often thought, I
mean, technologies like infrastructure, it's kind of
like being like I am, I work in Rd. because like I happened to
take one on the way to my office, you know, but I think
that there is a, it's, it is AI just had a conversation with one
legacy media outlet that's very concerned about like how, how do
its audience understand technology, etcetera.
And we're talking about it. And I'm like, it's kind of just
everything now. But Healthcare is a great way
into the topic because everybody cares so much about healthcare.
I mean, we're in a moment where obviously, you know, we saw in
New York City the killing of the United Healthcare CEO last year,
us all even this recent shooting that happened on Park Ave. with
NFLI mean there was a concussion background to it.
I think Healthcare is just such a human and real.
I mean, everything I say right now is going to sound so dumb
and earnest, but like it is it is the thing that touches all of
our lives and all of our parents lives from the moment we're
born. And when I started Smart Girl
Down questions, the first episode I did was Can
Billionaire Save us with Mark Cuban talking about capitalism
in healthcare. And he outlined this vision for
how private Healthcare is going to be the only way to get to a
kind of national single payer, single payer system over time.
So I just think it is the best place to talk about some of
these themes, including AI and including policy.
We went through some bad names. I for a second thought we should
call it Maha Valley. Eric was like, no.
Yeah, we got very close to that, but I think we clearly want to
reflect a couple different themes.
There was there was something with blood too that we like
really agonized over. Do you remember?
What it was, yeah. You wanted to call it something?
I was like, what is that? That sounds so.
Terrible. You wanted a video game.
So then I was like, I don't, I don't know if it was that or
there was some random summit, I can't remember.
I don't know. It was like, it was like finger
prick or something. I was like, OK, Elizabeth
Holmes, calm down. We're not going to.
We're not going to call it that. It's like.
Anyway, did you come up with? The one sort of the technology,
the sort of creation, you know, it's a little bit sci-fi.
If you're a regular listener to this podcast, you know that
ahead of Cerebral Valley, I'll have my coast.
Max and James, you actually I think are friends or you went to
Business School with Max, right? I did Max Style, dropped out of
Business School. He took his excellent voice.
He's too. You're always like, he's too
cool for school. Yeah.
So Max and James and I, you know, do an episode or two
before the conference just sort of like, you know, talking about
what's going to come. And I thought one of my favorite
pieces from those conversations is often they're just like, what
themes do you think are going to emerge?
So we don't want to, like, spoil everything.
Obviously, the joy of these events is like the unexpected.
And the answer is we don't know. But we're obviously diligent
journalists, so we've done prep calls.
So I wanted to play this game with Naima of just coming up,
each of us taking turns with three themes that we think will
emerge and that we're excited to sort of interrogate during Deus
Ex Medicina. OK, Are you ready?
Yeah. I mean, I didn't do my homework
because I'm like, oh, podcast, I do this.
We'll. Figure it out.
Yeah, yeah, but I love it. Why don't you go 1st and then
I'll be like you stole all my great ideas.
Now I I want to do better than next child.
Well, yeah, we all love a little.
This is very competitive, I think podcast, I mean.
Max already won because the like the trick is leaving but like
the most successful people leave.
Drop out of school. I think that's literally, I
think biology or I don't know, somebody gave a speech, I think
while he was a Business School. It was like, you need to drop
out. You know, it's classic Stanford,
everybody. Yeah, Max Child disciple of
biology. Yeah, that makes sense.
OK. The OK longevity is everywhere.
So longevity is nowhere. I think that with the rise of
GLP ones, it's like, yeah, duh, longevity.
It's like between statins and GLP ones.
Everyone clearly sees that helping pretty healthy people
have higher quality of life, longer life is is a big money
maker is a good idea, something that people want, something that
maybe consumers will even spend money on out of pocket.
And I think longevity has been this term.
That said, the medical world you don't embrace like life
extension. So we need to give it a
different name. But now with, you know, with
Govi and everything else, it's just clear that like this is a
big opportunity. And I think the questions will
be much more when does like sort of big pharma and everybody else
sort of explicitly say we're going after like anti ageing and
just embrace it themselves? But I think it's a matter of
when. OK, I love that.
Longevity is everywhere, so longevity the word is.
Nowhere or do I agree with that. The way I think about this in my
kind of smart call dumb questions framework is like, why
are millennials so optimistic that we want to live forever,
but so pessimistic that we don't want to procreate like what is
happening to our generation? But do I agree?
I think that longevity is very much in the zeitgeist and and
very much in our culture, but it is Americanized and commercial.
I think the experience of longevity in America is so
specific to the United States that even if you like go across
the pond to Europe, you do not see this obsession.
There's something uniquely American that is happening here
and I feel like the capitalist movement into the longevity
space is is an example of that. The use cases for GLP ones are
very particular in the United States as well.
You're seeing this commercialization and this
visualization of longevity in the United States.
Do I think it's everywhere? No, because I think it's like.
Because. It can take you see the.
World, it's like once capitalism has embraced it, it is
everywhere and you're like, oh, there's more than just whether
like every company in healthcare sees like, oh, this is a way to
make money That's like there's more to that, Eric, but.
But yeah, yeah. But but I do think it's a
profound moment because Americans are really
reconsidering like longevity and health and buying into that.
However, we know from the health data that we pay more than most
other countries. We have worse health care comes
than most other countries. You know, consternation around
what's in our food supply, what, you know, the what do we use
plastics in our ecosystem, whatever it is.
Like people are very concerned about their health, but it's all
happening in a relatively unregulated, highly capitalistic
and commercialized world. So I agree with you.
In the United States, longevity is now everywhere and therefore
it's nowhere. But I think in the rest of the
world it's nowhere and somehow it's everywhere.
No, there's a couple. Beats behind everybody else I
guess. No, but.
I I think actually what I'm saying is different.
Like the rest of the world, longevity is nowhere to be
discussed and everywhere to be had.
People are living. Yeah, I guess.
America needs the to meet, Yeah, match the lifespans of some
other countries. Exactly.
OK, I like that. Unpack there.
All right, now you're up. Should I?
Do 1. So I think that the future of
medicine is N of one. It is.
Expound I think I know what you're I learn the health lingo
a little bit, enough to know what you're saying, but explain,
explain it a little bit more like.
Even if you think about a concept like longevity that
we're talking about, it's no longer going to be about, oh,
you know, the average lifespan in the United States in the mid
70s and I'm going to live to the 90s.
It's like I based on my own biometric information, the
genetic data that I have, everything I know about myself,
you know, should be expected to live based on my parents
history, everything should be expected to live to, I don't
know, 87, but I believe that I can extend that to 100 and B and
I believe that I can be, you know, at age 39, feel like I'm
age 27. You know, that is what I mean.
It's so personalized and everything that you're seeing
and. There's obviously this big
movement in health around drugs that are like specifically
targeted to you in treatments and like, yes.
Exactly. That's where I was going to go.
For example, we're doing this one panel at at DS that's going
to be around Novel Biosciences and Therapeutics and we're going
to have a Janice Chen from Mammoth Biosciences as well as
Jacob Mccraft from Strand Therapeutics.
And if you look at what's happening in healthcare, like
the idea that you can find out what particular cancer somebody
has, what cells, what bad cells are replicating, how we go into
their genetic code to create individualized medicine,
individualized therapies. You know, some of this is
preclinical, but that is the future of medicine.
It is all going to be against yourself.
It is a very different world to operate in.
I don't know what it means for clinical care, et cetera, which
gets to my second theme, which I will not scoop myself on.
I my. My my one response to that,
Yeah. Tell me I definitely.
Think it's a trend, but I'm of two minds.
I think 11 pushback is just like if AI is really one of the
transformational forces, like it's desperate for data and in
some of the things people already want to do, like improve
drug discovery, their questions of like, does it have all the
data it needs to improve? How?
Like somebody was literally just telling me today, it's like, if
we're using AI to improve trials, we don't actually know
what occurring Alzheimer looks like.
So how does AI model that, right?
Because we don't even have the data.
And so then if you're saying, or are we going to make leaps with
the individual, it's like even harder for AI just to know, you
know, even on a system wide, let alone an individual.
And I get there are lots of different pieces of technology
happening at once, but I probably lean a little bit more
on the like there's a lot of work on like the big side on
the. General meta though, even there
are a lot of. People doing exactly what you're
saying, no. And I think there's probably
like some income distribution to this thing, which is like there
is going to be a group of people who, and you already hear about
people who are coming up with unique PCR tests and and funding
development of their own personalized mRNA vaccines for
their own type of cancer in their whatever it is.
So you're hearing stories about that happening.
Meanwhile, you're right, the big push is going to be on raw data,
but that I mean you in healthcare are an anecdote.
I just wore CGM for a couple of weeks because I'm seeing this
longevity doctor right now as a part of CGM continuous glucose
monitoring like levels. Remember the means.
Yeah, get what there be live forever.
What are you doing? I'm I, I, I think, I don't know
if I've said this on the podcast, I'm going to be open
about this, the event. I I've started taking Wigovi so
I'm deep in one of the. 1. Thing so at least on that front,
I'm I'm not the full medical dose.
I'm like the one before that. So it's an ongoing experiment.
So I'm I'm certainly in and I use like one medical or
whatever, but I'm not deep in I I wouldn't say, hey, I'm a super
health hacker. I'm always asking these health
people and I I'm sure I'll ask them at the event on Tuesday.
Some of them like do you do anything different?
And honestly, some of the more medical people, they're like,
no, I don't. I don't do anything weird like,
man. So it'll be interesting to see
if we can get anyone to say like, Oh yeah, I, I'm doing
something, no. I'm I'm super curious when I'm
speaking to Celine from loyal and Saju.
No, no, I just talked to her. I just talked to her spoil.
She doesn't do anything weird. She is like, hopefully.
Sage from Noom is doing some stuff.
She's like, no, you need to see studies and everything.
Like even sort of a big believer in longevity.
She's doing life extension for dogs which I'm super excited
Anyway going. To be so excited and Noom has
just gotten into a micro dosing GLP 1.
So one very cool. Thank you for sharing with us
about the Vicovia. I'm I'm so curious what you'll
learn from it. I've thought about it as well.
Like I've definitely talked to doctors about micro dosing.
I'm very worried about it because I'm worried about losing
any muscle mass. It was so important for, for
women to retain muscle mass and becomes harder in your mid to
late 30s and beyond. And so I something that I think
a lot about, Oh, I was going to say the CGM thing.
I just want to say one thing on CGM.
I was wearing the CGM and for example, like everyone will tell
you, oh, carbs, rice, whatever. Like I don't spike.
I don't spike with ice cream. I didn't spike with cookies.
I'm not saying it's not it's good.
I. Should try this.
I hate blood. You know, I'm like a big fainter
about blood, but you. Won't see any.
It just like it goes into your arm.
I know. And I take the shots with Govi
so and I gave, you know, my wife, I think I can say this,
all these IVF shots. So, you know, I'm used to, yes.
Well, I mean, now I'm doubly confused about why you wanted to
call it like blood point or whatever bad name you wanted to
give to our conference that I'm afraid of.
Blood. Well, it's just you got to lean
into your weaknesses. All right?
All right, Yeah, OK. Confront.
Your fears OK, second trend whether you got this is?
A big, big idea, but I'm just calling it friends to enemies.
Like I think there are a lot of these companies that are just
going to collide. You know, like certainly at all
our AI events, you know, Open AI, Anthropic, Loom large and
some of these companies build on top of them.
But they're trying to make sure it's like we need you, but we
can do our own thing. And then even all the companies
in the space they're raising, it's such high valuations that
they need to be everything. And so I think it's a small
world. Everybody knows each other, they
try to be friendly, but they also have these enormous
valuations that they need to justify.
And so I think there's going to be this, are we partners or are
we competitors? And.
I like it, yeah. I I kind of feel the frenemy
frenemy ship that's that's evolving even as we're, you
know, kind of prepping for this because partnerships are always
an interesting reality in the healthcare space.
I have a related one to this, which is race to the bundle.
Race to the bundles. I think this is like, you know,
I came up and kind of documentary film.
I worked briefly at Jason Kyler's vessel had phrase $125
million for like a short format video service that was going to
window YouTube content for three days.
I mean, I won't. I.
Know, you know, I turned down an offer to be like employee number
120 at Stripe to do that. It's on my list of interesting
decisions. Yeah.
But but what I will say is, you know, what you, what you've seen
in the streaming wars, I think is, is really interesting
because of this push, because of the trends that are happening,
which is consumers as payers and increasingly subscription fees
versus fee for service, which has been the historical model of
healthcare delivery. You have data at your fingertips
and subscription pay versus, you know, data in the hand of the
clinician and fee for service. That's been on a huge shift.
And as a result of that, I think it's like, OK, consumers are
going to be like, well, how many, you know, I don't want to
pay for Peacock and Netflix and Hulu and whatever.
I love all you guys, Peacock and Netflix, Hulu, we love you guys
of my pod, some of you. But I do think that there's
going to be kind of a reckoning where not everyone can.
Who are the big IPO? That's a big question I have.
Who do you think are the big IP OS?
Because I think we have some big IP OS coming to our conference
future. Interesting.
I mean, it's going to take a while.
The funny thing is that this space has extreme hype and
extreme pessimism in that biotech has been in a terrible
downturn. But obviously computational AI
based companies are raising a massive valuations and biotech
companies are traditionally the ones that like go public early
on. Where is the highly valued AI
startups are like, I'll just raise from the private market.
So I honestly, I don't have a great read on who's like about
to go out. It's sort of a mixed.
It's like, who can frame themselves which way?
Yeah. I'll be curious to see, but I do
think that some of these, you know, you have these companies
that are all of a sudden, I think, you know, Aura did a
partnership with, I'm going to forget the name, but Aura did a
partnership with the CGM company.
Now you know what CGMS are. So, you know, and it's not wear
it all the time and it's something that the ring can't
do, but it is, you know, how do you integrate that data around?
They've always had this idea of experimentation at Aura.
So like, can you not? Drink coffee for a couple weeks,
can you not? And so this is a kind of in the
model of experimentation, they can have these partnerships that
are going to teach their consumers so much.
The question is over time, do you develop a bundle?
Do you acquire these companies you vertically integrate?
Are you doing everything or does some strategic just come in and
buy the thing? All right.
So that was about bundling. Bundling.
Services and companies. My third and final theme is
drama blinders. It's like there have been major
changes at the, you know, CDC obviously Maha is, you know,
proposing a lot of things. Some people in the medical
community will have, you know, are certainly more Dem aligned,
I think. But I think that honestly, more
than I think people sort of, I don't, I'm really interested to
see, but I think a lot of people are going to be like doing my
thing. I'm happy to work with the
government where it's possible, like excited that they're taking
swings. I don't know.
I think there will be a lot of, there's so much going on.
There's so much opportunity. I I think that there's going to
be some desire to avoid. Confrontation not.
Just with the administration, but just sort of like, you know,
exact like this fitting with my first theme, like the longevity.
It's like these are not the Brian Johnson's types.
Like I I didn't extend, we didn't extend an invitation to
Brian Johnson here partially because I wanted sort of like
the real like a builder class of people here.
And I do think a lot of the people who are going to be
speaking are like, not necessarily trying to, you know,
they're not selling like what some, you know, I don't know,
like what what are they even called supplement or whatever.
You know, I, I just think we're not going to have sort of the
grifter class here, which you can often see in longevity.
And we're not going to see people looking to like, fight
with the administration. And so drama blinders maybe
doesn't even fully capture it. It's sort of like, yeah, hard at
work. Focus on their thing.
I don't know. You know, since the pandemic,
there has been this real politicization of healthcare.
We have seen for sure. And it is even through this last
week when we have seen the CDC appointee from the Trump
administration is no longer holding the job.
All of a sudden, there's been a, you know, acting CDC director
appointment for Deputy Health Secretary Jim O'Neill.
I mean it makes. Sense I mean this is these are
his people he was in Silicon Valley.
Like, I think for the Trump administration to have a super
positive health agenda besides, you know, maybe something like
the food quality stuff, having us sort of work around what's
happening in AI makes a lot of sense.
So yeah. So it's it's a natural place for
him to be. Yeah.
So. Jim O'Neill's has roots in
Silicon Valley, had worked in HHS under, you know, Bush 43
administration, had been the CEO of the Teal Foundation, worked
at various investment firms in the Valley for a long time.
But there is a really interesting shake up happening
in American healthcare. There is a lot of media coverage
about that. I think that there is a real
question around future of science, the role of private
sector companies, role of the public sector.
You're seeing and the big beautiful bill cuts to you know,
health provision programs, particularly Medicaid.
You're also seeing these big off branches extended to private
companies. New more companies are actually
working with CMS and HHS on this great data collection.
I'm really interested to hear about what what is the future of
healthcare? What is the conversation that's
happening in Washington, What it what is the role of Silicon
Valley, what is the role of science, etcetera.
We have a lot to discuss, but my last theme, the end of privacy.
Oh, interesting. That's a good difference like.
What even is HIPAA anymore? Right?
Like HIPAA who? Wants it, you know.
Like all of a sudden silicon. Valley alive on it.
But it's just like for all of us.
You're taking, you're putting devices to yourself.
It's just like, yeah, I feel like, by the way.
I am like somebody who doesn't have my memory on on Chachi PT
and I'm like, let me give you my minute to minute blood glucose
data. You know, I never have been a
big privacy person I want. These companies have the.
Information, yeah. And that's where I think the
integration is really interesting.
And that's actually where, I think, you know, there's been
some surprising moves out of DC, including, you know, the stake
and Intel, right? We did not expect a Republican
Party to be doing, you know, joint stock ventures in the mode
of, you know, percentage stakes in private companies.
I used to see that when I worked in Vietnam in my past 100 lives.
But they are the ones that they're pushing for this great
data integration across all these streams.
Now, there's also a lot of, you know, concerns about that you
hear, particularly for women and their fertility.
I'm curious to talk to Maven and Nora about this.
Like, there's a lot happening unfolding in the world of
privacy and data. And what does your private
health data mean? And can it save other people's
lives as you know, mission to actually sharing?
I'm interviewing Han Pack, you know, Samsung's top health
executive and obviously they take data very seriously.
I mean, they have an interesting position that a lot of their
devices customers are not buying in necessarily with health as
the first and only thing. So you have to balance what do
people think about this devices for while providing value to
people who want health information.
And so I think they're interesting trade-offs there,
yeah. So we'll see.
End of privacy, maybe the end of longevity.
Frenemies galore. This is going to be so much fun.
Longevity in a in it's sort of gone mainstream moment.
Yeah, I'm I'm really excited. I think there's a lot we're not
even thinking about yet. I mean the potential, you know,
if any one of these companies that we talked to discovers, you
know, the next satin, the next GLP one, it'll be amazing.
You know, 1 discovery like that could be transfer informational.
I think, you know, on the flip side in AI, I think, you know,
while we've seen progress from people like Alphabet and there's
still like, you know, AI producing novelty is still in my
mind an open question as somebody who follows this.
Seriously. And.
There's nowhere we want it more than in health, right?
We want some novel thing that humans couldn't figure out.
And so I think taking the temperature on everybody on,
like, will AI be able to produce something new?
I'll be interested to hear. Yes, I, I mean, one thing I
didn't mention and it was part of my kind of end of 1 thesis is
this huge move into genomics and baby sequencing.
We have Robert Green coming from Harvard Medical School.
He's done the he's overseeing the greatest kind of genetic
sequencing project as it relates to babies and children.
That was done in the UK where there is a preponderance of
data. So I think like the unlocking of
data allows a ton of research, a lot, a lot of discovery.
It's a huge shift. But like, I think we should add
on a bit of a sci-fi future prediction of the.
But there is something in, you know, in the film Gattaca or, or
as my cousin in Pakistan, Omar called it when we went to rent
it from the movie store, Gattaca, Gattaca, the Ethan
Hawke film. You know what I'm talking about.
Gattaca. I've heard of it.
Yeah, yeah. I don't know.
I don't know if I've actually watched it it.
Was like, really? It's like from like, I'm like
sci-fi. Babies.
But this idea of like kind of choosing your baby and what
color eyes, etcetera, etcetera. I mean, we're in a world where
that is not, that is not necessarily where we're going,
but the idea that you can know from the, you know, from, from
the biology and the genetics of an embryo or a newly born child
what is likely to happen to them in the course of their life.
And that they could maybe have customized healthcare that
anticipates that, sees the signs of that early on and potentially
has customized drugs to deal with these interventions.
I mean, how we're going to do this at scale for everybody.
And this doesn't become like a great luxury, like the great
business class of Healthcare is going to be something to say,
but we've already seen so much real technological movement and
a lot of this is going to be unleashed through AI.
It's like the back end stuff. And a lot of these companies
that we're seeing of how using AI and clinical trials, how are
you seeing AI optimize A diagnosis?
Those companies are, yeah. I mean, my other, you know,
personal health journey is just, you know, my wife weeded out
Bracha from our child that is due soon after this conference.
So it'll be interesting. I'm obviously that's a deeply
personal theme. And then I'll be seeing this
whole conference just from the perspective of what what's my
kid going to get or like what's what's this kid going to benefit
from? And it definitely gives you, you
know, it'll give me a different perspective.
Wait, Naima. So excited to do this.
I think it's going to be a really fun event.
Obviously, not everybody listening to this is going to
get to go in person, but we will be publishing videos as always
from the event and writing up sort of the key takeaways in the
sub stack. So subscribe to Newcomer and go
listen to smart Girl dumb questions.
Naima Raza, thanks so much for doing this with me.
Thank. You so much Eric gives me fun.
See you on Tuesday. Sounds good.
All right. See ya.
Bye.